Experimental pill aims to ease sun sensitivity in rare blood disorder
NCT ID NCT07024316
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests an oral drug called ATL-001 (ciclopirox) in 6 adults with congenital erythropoietic porphyria (CEP), a rare condition that causes severe skin damage from sunlight. The study measures whether the drug reduces skin lesions, fatigue, and other symptoms over 12 weeks. Because it is a small, open-label study, results are preliminary and may not apply to all patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ATL-001 (ciclopirox oral solution)
- What this could lead to
- If it works, this could point toward a treatment that reduces painful skin lesions and fatigue in people with CEP.
- What could go wrong
- This is a very early, small trial with only 6 participants, so results may not apply to everyone. The drug may not improve symptoms or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ERYTHROPOIETIC PORPHYRIA (CEP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Cleveland Clinics
RECRUITINGCleveland, Ohio, 44195, United States